|Chemical and physical data|
|Molar mass||604.39256 g/mol|
|3D model (Jmol)||Interactive image|
ICI-85966 (former tentative brand name Stilbostat), also known as diethylstilbestrol bis(di(2-chloroethyl)carbamate), is a synthetic, non-steroidal estrogen and alkylating antineoplastic agent of the stilbestrol group and a cytostatic nitrogen mustard ester of diethylstilbestrol (DES) that was developed for the treatment of breast cancer and prostate cancer but was never marketed. It was found to markedly improve the clinical state in approximately 65% of women treated with it for advanced breast cancer in a clinical study.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 397. ISBN 978-1-4757-2085-3.
- Zimel H, Broder D, Zimel A (1973). "[Therapeutic effects of the preparation "Stilbostat" in advanced stages of breast cancer after the menopause]". Stud Cercet Endocrinol (in Romanian). 24 (3): 211–9. PMID 4703920.
- Görlich M, Heise E (1976). "Contribution to the mechanism of Stilbostat action". Neoplasma. 23 (4): 363–9. PMID 1004653.
- Zimel H, Mogos I, Maltezeanu G (1977). "Estimation of StilbostatR treatment efficiency in breast cancer by thermography". Neoplasma. 24 (5): 553–7. PMID 927612.
- Zimel H, Bocancea D (1974). "Treatment of prostatic carcinoma with Stilbostat". Neoplasma. 21 (1): 101–8. PMID 4596007.